Will a gene therapy that edits multiple genes using CRISPR be approved by the FDA before 2030?
Basic
24
1.0k
2030
75%
chance

In late 2023 the United States Food and Drug Administration (FDA) approved Casgevy, the first ever CRISPR-based gene therapy. Casgevy is a gene therapy for sickle cell disease, which is a hereditary disease caused by a mutation in a single gene (i.e. it’s monogenic).

To count as a YES, a “gene therapy that edits multiple genes using CRISPR” should modify two or more genes in a patient’s genome by using some version of CRISPR (e.g. Cas9, an alternative protein). The gene therapy must be for humans.

Will the FDA approve a multigenic gene therapy using CRISPR technology before 2030?

Get Ṁ600 play money

More related questions